Adjuvant aromatase inhibitors and emerging quality-of-life considerations

In summary, while AIs are a welcome addition to the repertoire of endocrine interventions for the treatment of breast cancer, further studies are warranted to elucidate their long-term effects. Other tumor-related characteristics and host factors may predict not only efficacy but also AI-associated safety. Early recognition and management of adverse effects is crucial for maintaining adherence and achieving the maximum benefit from therapy. Additional follow-up is required to establish the long-term safety of the agents. Until further information becomes available, clinicians are encouraged to utilize AIs in the setting in which they have been studied and approved.